Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA discusses the possibility of exploiting the biology of the plasma cell for drug therapy in multiple myeloma (MM). Prof Boise mentions the targeting of the cell surface proteins CD28 and CD86 and translating findings into clinical practice.
Recorded at the Myeloma 2016 meeting held in Boston, MA.